Article
Medicine, Research & Experimental
Jian Zhang, Yu Chen, Mei Ding, Zhongping Duan
Summary: This study found that the levels of FT3 and its dynamic changes are associated with the 90-day prognosis of patients with HBV-ACLF. The prediction of prognosis can be improved by combining FT3 with HE grading. Comparing different scoring methods, the FT3 correlation formula score showed higher accuracy in predicting prognosis.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Ye Xiong, Zuoxun Xia, Lu Yang, Jianrong Huang
Summary: This study investigated the relationship between low triiodothyronine syndrome (LT3S) and poor prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). The results showed that LT3S was an independent risk factor for 28-day mortality and was correlated with poor prognosis.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Oncology
Feng Li, Ying Zhang, Zhao-Hui Wang, Shuai Gao, Yu-Chen Fan, Kai Wang
Summary: Glucocorticoid treatment can reduce mortality in patients with acute-on-chronic hepatitis B liver failure (ACHBLF). The methylation of suppressor of cytokine signaling (SOCS) 1 is associated with mortality in ACHBLF patients.
CLINICAL EPIGENETICS
(2023)
Article
Medicine, General & Internal
Yuji Shimizu, Shin-Ya Kawashiri, Yuko Noguchi, Seiko Nakamichi, Yasuhiro Nagata, Naomi Hayashida, Takahiro Maeda
Summary: The study showed a complex association between FT3/FT4 and CKD and SCH, with FT3/FT4 positively associated with SCH but negatively associated with CKD, suggesting that higher activity of peripheral thyroxin deiodination might be beneficial in preventing CKD.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Na Hu, Xian-Ci Xie, Lin-Lin Liu, Wei-Dong Lai
Summary: The study identified UBE2Q1 gene promoter methylation as a potential biomarker for predicting and diagnosing ACHBLF, with hypomethylation associated with the severity of the condition. The UBE2Q1 promoter methylation status combined with the model for end-stage liver disease score showed high sensitivity and specificity for early diagnosis of ACHBLF.
Article
Gastroenterology & Hepatology
Xiaoting Tang, Tingting Qi, Beiling Li, Hai Li, Zuxiong Huang, Zhibin Zhu, Minghan Tu, Jie Gao, Congyan Zhu, Xiuhua Jiang, Xutong Yu, Guanting Lu, Ming Xiong, Qinjun He, Fuyuan Zhou, Weiqun Wen, Jinjun Chen, Jinlin Hou
Summary: The study compared the three clinical types of ACLF patients and found that type-A patients were younger with higher platelet counts, aminotransferase levels, and more active HBV replications compared to type-B and type-C. Different types of ACLF patients showed significant differences in liver, kidney, and coagulation failure, as well as short-term mortality rates.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Medicine, General & Internal
Dakai Gan, Yuyu Zeng, Kaige Zhang, Yang He, Jiao Wan, Xiaoqing Zhang, Zhen Zhang, Longchuan Zhu, Tao Long, Nengwen Xie, Bo Zou, Xuezhen Zhang, Yunfeng Xiong, Guoliang Feng, Daya Luo, Molong Xiong
Summary: This study aims to establish a more efficient prognostic assessment system for hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). By analyzing data from 623 patients, a new scoring system was developed using results from the first reexamination, first examination, mean daily change, and other first examination results. The final prognostic scoring system accurately predicted 90-day mortality and patients with lower scores had longer survival times.
Article
Medicine, Research & Experimental
Hong Shi, Gemin Xiao, Mei Liao, Lihua Zheng, Yusheng Jie, Guoli Lin, Yutian Chong
Summary: Inappropriate cessation of nucleos(t)ide analog therapy is associated with poor prognosis in patients with HBV-related ACLF, with lower short-term and long-term survival rates in patients using NAs and higher risk for liver transplantation.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Gastroenterology & Hepatology
Fangwan Yang, Yujuan Liu, Baimei Zeng, Jun Chu, Han Hu, Yanqing Yang, Huan Chen, Caiyun Tian, Ying Li, Shide Lin
Summary: The Lok index has strong predictive accuracy for progression to ACLF in patients with acute exacerbation and severe exacerbation of chronic HBV infection, requiring different thresholds of liver fibrosis based on severity of liver injury.
HEPATOLOGY INTERNATIONAL
(2021)
Article
Pharmacology & Pharmacy
Yu Liu, Wei Yuan, Miao Fang, Hongying Guo, Xin Zhang, Xue Mei, Yuyi Zhang, Longshan Ji, Yating Gao, Jiefei Wang, Zhiping Qian, Man Li, Yueqiu Gao
Summary: This study aimed to estimate the serum levels of high mobility group protein 1 (HMGB1) in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) and analyze its clinical value in the development and outcomes of acute kidney injury (AKI). The results showed that the incidence of AKI in HBV-ACLF patients was 61.0%, and HMGB1 levels were associated with the severity and prognosis of AKI. Therefore, HMGB1 may be a potential predictive factor for the development and prognosis of AKI.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, Research & Experimental
Shuai Gao, Li-Yan Han, Yu-Chen Fan, Kai Wang
Summary: This study aimed to establish a noninvasive model for predicting the 90-day mortality in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) who received glucocorticoid therapy. The HITAS score, based on hepatic encephalopathy grade, INR, total bilirubin, age, and SIRS status, showed better predictive value for 90-day mortality of HBV-ACLF compared to other scoring systems. The HITAS score can help identify HBV-ACLF patients with favorable responses to glucocorticoid treatment.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Xueyun Zhang, Yue Ying, Pu Zhou, Xiaoqin Liu, Ruidong Li, Yifeng Tao, Minhui Dong, Beidi Zhu, Xun Qi, Qianqian Wang, Xiaofei Zhang, Jingwen Wu, Jianming Zheng, Weifeng Zhao, Wenhong Zhang, Zhengxin Wang, Jiming Zhang, Yuxian Huang
Summary: The study found a relationship between the COSSH-ACLF grades of HBV-ACLF patients at 3-7 days after diagnosis and the final confirmation. For patients with poor prognosis, urgent liver transplantation may improve survival rates; however, the necessity of liver transplantation for patients with good prognosis remains unclear.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Immunology
Jingjing Tong, Hongmin Wang, Xiang Xu, Zhihong Wan, Hongbin Fang, Jing Chen, Xiuying Mu, Zifeng Liu, Jing Chen, Haibin Su, Xiaoyan Liu, Chen Li, Xiaowen Huang, Jinhua Hu
Summary: This study aimed to verify the efficacy of G-CSF in HBV-ACLF patients and explore its effect on monocytes. The results showed that G-CSF treatment can improve the survival rate of HBV-ACLF patients by reducing the expression of M1 markers and increasing the expression of M2 markers in monocytes, promoting their reparative and anti-inflammatory functions.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Xiaohui Liu, Jing Zhang, Xinhuan Wei, Zhongping Duan, Hongqun Liu, Yu Chen, Yali Liu, Samuel S. Lee
Summary: There are significant differences in clinical manifestations and prognosis between type A and type B hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF). Type A patients have more severe liver inflammation, while type B patients are more likely to develop extrahepatic organ failure and have a poorer prognosis.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Daxian Wu, Qunfang Rao, Zhongyang Xie, Xiaoqing Zhu, Yuanmei Che, Jian Wu, Hainv Gao, Jingyu Zhang, Zhouhua Hou, Xiaoyu Cheng, Zeyu Sun
Summary: The study identified VDBP as an independent prognostic biomarker for HBV-related ACLF, with VDBP levels closely linked to organ failure and showing value for monitoring ACLF progression.
CLINICAL AND MOLECULAR HEPATOLOGY
(2022)